Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-3288 in Relapsed/Refractory Hematological Malignancies
NCT07424833Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of APG-3288 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and 4 more (2 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose-limiting toxicities at 28 days, Treatment emergent adverse events and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
APG-3288
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07424833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424833.